Loading
Life sciences · Journal article
Postgraduate Medicine · September 18, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Plain Language SummaryWhat is this summary about?Metabolic dysfunction–associated steatotic liver disease, or MASLD, and its severe form, metabolic dysfunction–associated steatohepatitis, or MASH, impose significant global burdens on patients and healthcare systems. It is important to identify people with MASLD and MASH, as these conditions can lead to serious health issues if untreated, like cirrhosis, liver failure, and liver cancer. Disease worsening also risks worsening non-liver-related conditions linked to obesity and metabolic dysfunction.Scientific society guidelines recommend using non-invasive tests in primary care to screen for MASLD and MASH risk, and support referral and treatment decisions. These guidelines recommend calculating the Fibrosis-4 Index score, which is based on age and blood tests. If scores are elevated, patients are recommended to undergo further testing for MASH and cirrhosis. Secondary tests include ultrasound elastography, magnetic resonance imaging techniques, or Enhanced Liver FibrosisTM blood-based test.Non-invasive tests may also be used to determine patient eligibility for treatment with resmetirom or semaglutide, approved therapies for MASH with advanced fibrosis without cirrhosis, and to assess treatment response. Wide-scale use of non-invasive tests in primary care could help identify people with MASLD and MASH risk, enabling timely treatment, slowing of disease worsening, and prevention of serious health complications and deaths.